SynAct Pharma AB (SYNACT.ST)

SEK 23.15

(15.17%)

Long Term Debt Summary of SynAct Pharma AB

  • SynAct Pharma AB's latest annual long term debt in 2023 was 58 Thousand SEK , down -94.55% from previous year.
  • SynAct Pharma AB's latest quarterly long term debt in 2024 Q3 was - SEK , down 0.0% from previous quarter.
  • SynAct Pharma AB reported annual long term debt of 1.06 Million SEK in 2022, down -49.57% from previous year.
  • SynAct Pharma AB reported annual long term debt of 2.11 Million SEK in 2021, down 0.0% from previous year.
  • SynAct Pharma AB reported quarterly long term debt of - SEK for 2024 Q3, down 0.0% from previous quarter.
  • SynAct Pharma AB reported quarterly long term debt of 24 Thousand SEK for 2024 Q1, down 0.0% from previous quarter.

Annual Long Term Debt Chart of SynAct Pharma AB (2023 - 2014)

Historical Annual Long Term Debt of SynAct Pharma AB (2023 - 2014)

Year Long Term Debt Long Term Debt Growth
2023 58 Thousand SEK -94.55%
2022 1.06 Million SEK -49.57%
2021 2.11 Million SEK 0.0%
2020 - SEK 0.0%
2019 - SEK 0.0%
2018 - SEK 0.0%
2017 - SEK 0.0%
2016 - SEK 0.0%
2015 - SEK 0.0%
2014 - SEK 0.0%

Peer Long Term Debt Comparison of SynAct Pharma AB

Name Long Term Debt Long Term Debt Difference
Active Biotech AB (publ) 3 Million SEK 98.067%
Biovica International AB (publ) 4.29 Million SEK 98.65%
Cantargia AB (publ) - SEK -Infinity%
CombiGene AB (publ) - SEK -Infinity%
Cyxone AB (publ) 74 Thousand SEK 21.622%
Diagonal Bio AB (publ) - SEK -Infinity%
Elicera Therapeutics AB (publ) - SEK -Infinity%
ExpreS2ion Biotech Holding AB (publ) 1.43 Million SEK 95.961%
Fluicell AB (publ) - SEK -Infinity%
Infant Bacterial Therapeutics AB (publ) - SEK -Infinity%
Mendus AB (publ) 850 Thousand SEK 93.176%
Isofol Medical AB (publ) - SEK -Infinity%
I-Tech AB - SEK -Infinity%
Intervacc AB (publ) 142 Thousand SEK 59.155%
Lipigon Pharmaceuticals AB (publ) - SEK -Infinity%
Magle Chemoswed Holding AB (publ) 32.58 Million SEK 99.822%
Modus Therapeutics Holding AB (publ) - SEK -Infinity%
OncoZenge AB (publ) - SEK -Infinity%
Sprint Bioscience AB (publ) - SEK -Infinity%
Xbrane Biopharma AB (publ) 112.89 Million SEK 99.949%
Lipum AB (publ) 1.76 Million SEK 96.706%
Alligator Bioscience AB (publ) 7.51 Million SEK 99.228%
Ziccum AB (publ) 286 Thousand SEK 79.72%
BioArctic AB (publ) 2.15 Million SEK 97.305%
Genovis AB (publ.) 74.8 Million SEK 99.922%
Camurus AB (publ) 13.61 Million SEK 99.574%
IRLAB Therapeutics AB (publ) 24.51 Million SEK 99.763%
Bio-Works Technologies AB (publ) - SEK -Infinity%
Aptahem AB (publ) - SEK -Infinity%
Vicore Pharma Holding AB (publ) - SEK -Infinity%
Xspray Pharma AB (publ) 31.94 Million SEK 99.818%
Kancera AB (publ) - SEK -Infinity%
Saniona AB (publ) 65.23 Million SEK 99.911%
Spago Nanomedical AB (publ) - SEK -Infinity%
AcouSort AB (publ) - SEK -Infinity%
Xintela AB (publ) - SEK -Infinity%
Abliva AB (publ) 424 Thousand SEK 86.321%
Karolinska Development AB (publ) - SEK -Infinity%
Amniotics AB (publ) - SEK -Infinity%
2cureX AB (publ) - SEK -Infinity%
Asarina Pharma AB (publ) 1 Million SEK 94.2%
Calliditas Therapeutics AB (publ) 939.5 Million SEK 99.994%
Hansa Biopharma AB (publ) 844.9 Million SEK 99.993%
Biosergen AB - SEK -Infinity%
QuiaPEG Pharmaceuticals Holding AB (publ) - SEK -Infinity%
Corline Biomedical AB - SEK -Infinity%
NextCell Pharma AB - SEK -Infinity%
Nanologica AB (publ) 136 Thousand SEK 57.353%
LIDDS AB (publ) - SEK -Infinity%
Egetis Therapeutics AB (publ) 103.4 Million SEK 99.944%
BioInvent International AB (publ) 14.53 Million SEK 99.601%
Annexin Pharmaceuticals AB (publ) - SEK -Infinity%
Stayble Therapeutics AB (publ) 850 Thousand SEK 93.176%
Alzinova AB (publ) 800 Thousand SEK 92.75%
Ascelia Pharma AB (publ) 176 Thousand SEK 67.045%
Oncopeptides AB (publ) 106.48 Million SEK 99.946%
Pila Pharma AB (publ) - SEK -Infinity%
Guard Therapeutics International AB (publ) - SEK -Infinity%
Scandinavian ChemoTech AB (publ) - SEK -Infinity%
Simris Alg AB (publ) 90.74 Million SEK 99.936%
Diamyd Medical AB (publ) 30.67 Million SEK 99.811%